References:
- Alcon Saez, JJ, A De Arriba Munoz, C Latre Gorbe, L Perez-Carbonell, T Villalobos, und O Duran Morgan. «Cost-consequence analysis for recombinant human growth hormone treatment administered via different devices in children in Spain.» Salud 17, Nr. 4 (2022): 91-107.
- Boye, KS, LS Matza, KN Walter, und et al. «Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.» The European journal of health economics: HEPAC: health economics in prevention and care 12, Nr. 3 (2010): 219-230.
- Brod, M, K.W. Lee, und M.H. Rasmussen. «First report of disease-specific patient-reported outcomes from a randomized phase 2 trial of once-weekly somapacitan versus daily GH in children with GHD.» Horm. Res. Paediatr. 93 (2020): 71–72.
- Deal, CL, J Steelman, E Vlachopapadopoulou, und et al. «Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study.» J Clin Endocrinol metab 107, Nr. 7 (2022): e2717–e2728.
- Foo, J, M Maghnie, A Colao, I Vlachaki, und G Colombo. «Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy.» ClinicoEconomics and Outcomes Research 11 (2019): 525-537.
- Gomez, R, SF Ahmed, M Maghnie, T Tanaka, BS Miller, und D Li. «Treatment Adherence to Injectable Treatments in Pediatric Growth Hormone Deficiency Compared With Injectable Treatments in Other Chronic Pediatric Conditions: A Systematic Literature Review.» Front Endocrinol (Lausanne) 13 (2022): 795224.
- Guidelines, NICE. «Human growth hormone (somatropin) for the treatment of growth failure in children.» 2010.
- Iglay, K, X Cao, P Mavros, K Joshi, S Yu, und K Tunceli. «Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy.» Clinical Therapeutics 37, Nr. 8 (2015): 1813-1821.
- Lindsay, R, M Feldkamp, D Harris, und J & Ral Robertson. «Utah Growth Study: Growth standards and the prevalence of growth hormone deficiency.» Journal of Pediatrics 125 (1994): 29-35.
- Maggio, MC, B Vergara, und P Porcelli. «Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre.» Ital J Pediatr 44 (2018): 113.
- Pollock, RF, AM Kappelgaard, und L Seitz. «An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices.» Expert Opin Drug Deliv 12, Nr. 3 (2015): 353-360.
- Qiao, Q, MJMN Ouwens, S Grandy, K Johnsson, und K Kostev. «Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany.» Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress 9 (2016): 201-205.
- Rivolo, Simone, Jane Loftus, Peter Balazs, Marion Fahey, und Thitima Kongnakorn . «Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland.» Journal of Medical Economics 26, Nr. 1 (2023): 963-972.
- Taddeo, D, M Egedy, und JY Frappier. «Adherence to treatment in adolescents.» Paediatrics & child health 13, Nr. 1 (2008): 19-24.